Comparative effectiveness of general practitioner versus pharmacist dosing of patients requiring anticoagulation in the community

Journal of Clinical Pharmacy and Therapeutics

Volumn 25, Issue 1, 2000, Pages 49-54

  Holden, Jill ^a,c   Holden, K ^b  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^b University Hospital of Hartlepool   (United Kingdom)

^c TYNE AND WEAR NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT;

ADULT; AGED; ANTICOAGULATION; ARTICLE; FEMALE; GENERAL PRACTITIONER; HEALTH CARE QUALITY; HEART ATRIUM FIBRILLATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PHARMACIST; RETROSPECTIVE STUDY; THROMBOEMBOLISM; VALVULAR HEART DISEASE;

AGED; ANTICOAGULANTS; FEMALE; HUMANS; MALE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; PHARMACISTS; PHYSICIANS, FAMILY; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0034025258     PISSN: 02694727     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2710.2000.00262.x     Document Type: Article

References (17)

1. 1. European Atrial Fibrillation Trial Study Group. (1993) Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet, ii, 1255-1262.
2. 2. Stroke Prevention in Atrial Fibrillation investigators. (1994) Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation. Stroke Prevention in Atrial Fibrillation II Study. Lancet, 343, 687-691.
3. 3. Levine H, Pauker S, Eckman M. (1992) Antithrombotic therapy in valvular heart disease. Chest, 102, 434S-444S.
4. 4. Stein P, Albert J, Copeland J, Dalen J, Turpie A. (1995) Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. Chest, 108, 371S-379S.
5. 5. Ginsberg J. (1996) Drug therapy: management of venous thromboembolism. New England Journal of Medicine, 335, 1816-1828.
6. 6. Evans JM, Henderson LE, Goudie B, MacDonald TM, Davey PG. (1997) Demand for warfarin anticoagulation monitoring in Tayside, Scotland. Health Bulletin, 55, 88-93.
7. 7. Sudlow M, Thomson R, Thaites B, Rodgers H, Kenny RA. (1998) Prevalence of atrial fibrillation and eligibilty for anticoagulants in the community. Lancet, 352, 1167-1171.
8. 8. Stafford RS, Singer DE. (1996) National patterns of warfarin use in atrial fibrillation. Archives of Internal Medicine, 156, 2437-2541.
9. 9. Anon. (1998) Pharmaceutical care awards report. Pharmaceutical Journal, 261, 25.
10. 10. British Committee for Standards in Haematology. (1998) Haemostasis and Thrombosis Task Force. Guidelines on oral anticoagulation. 3rd edn. British Journal of Haematology, 101, 374-387.
11. 11. Radley AS, Hall J. (1994) The establishment and evaluation of a pharmacist-developed anticoagulant clinic. Pharmaceutical Journal, 252, 91-92.
12. 12. Gray DR, Garabedian-Ruffalo SM, Chretien SD. (1985) Cost justification of a clinical pharmacist managed anticoagulant clinic. Drug Intelligence and Clinical Pharmacy, 19, 575-580.
13. 13. Bussey HI, Rospond RM, Quandt CM, Clark GM. (1989) The safety and effectiveness of long-term warfarin therapy in an anticoagulation clinic. Pharmacotherapy, 9, 214-219.
14. 14. Pell JP, McIver B, Stuart P, Malone DNS, Alcock J. (1993) Comparison of anticoagulant control among patients attending general practice and a hospital anticoagulant clinic. British Journal of General Practice, 43, 152-154.
15. 15. Poller L, Shiach CR, MacCallum PK, et al. (1998) Multicentre randomised study of computerised anticoagulant dosage. Lancet, 352, 1505-1509.
16. 16. Rose P. (1996) Audit of anticoagulant therapy. Journal of Clinical Pathology, 49, 5-9.
17. 17. Hardman MC, Cowie MR. (1999) Anticoagulation in heart disease. British Medical Journal, 318, 238-244.